XANAX TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
20-04-2023
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
ALPRAZOLAM
Inapatikana kutoka:
BGP PHARMA ULC
ATC kanuni:
N05BA12
INN (Jina la Kimataifa):
ALPRAZOLAM
Kipimo:
0.5MG
Dawa fomu:
TABLET
Tungo:
ALPRAZOLAM 0.5MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
15G/50G
Dawa ya aina:
Targeted (CDSA IV)
Eneo la matibabu:
BENZODIAZEPINES
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0115008002; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2020-05-01
Tabia za bidhaa
PRODUCT MONOGRAPH
XANAX
®
alprazolam tablets USP
0.25 mg, 0.5 mg and 1 mg tablets
XANAX TS
®
alprazolam tablets USP
2 mg triscored tablets
ANXIOLYTIC - ANTIPANIC
BGP Pharma ULC
85 Advance Road
Etobicoke, Ontario
Canada, M8Z 2S6
Submission Control No: 273630
®
UPJOHN US 2 LLC
BGP Pharma ULC, a Viatris company, Licensee
©
BGP Pharma ULC, 2023
Date
of
Preparation:
APR
20, 2023
_ _
_XANAX and XANAX TS (alprazolam) _
_–_
_ Product Monograph _
_Page 2 of 41_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................4
CONTRAINDICATIONS
...................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................14
DRUG INTERACTIONS
..................................................................................................18
DOSAGE AND ADMINISTRATION
..............................................................................21
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................24
STORAGE AND STABILITY
..........................................................................................25
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................27
PHARMACEUTICAL INFORMATION
..........................................................................27
CLINICAL TRIALS
.........................
Soma hati kamili
